From biologics to treatments for rare diseases, these drugs will bring unique production challenges that require advanced technologies and precise processes.
India’s contract development and manufacturing organization market is expected to grow from $7 billion to $14 billion by 2028, capturing 4% to 5% of the global CDMO market.
Evergreen’s scalable manufacturing capabilities are meant to enhance Lantheus Holdings’ ability to meet the complex demands of radiopharmaceutical development and production.
